.Pharmacolibrary.Drugs.ATC.N.N05AF05 .Pharmacolibrary.Drugs.ATC.N.N05AF05| name: | Zuclopenthixol |
| ATC code: | N05AF05 | route: | oral |
| n-compartments | 1 |
Zuclopenthixol is a typical antipsychotic drug of the thioxanthene class, primarily used for the treatment of schizophrenia and other psychotic disorders. It is available in several formulations, including oral and long-acting intramuscular preparations. The drug remains in clinical use for managing agitation, aggression, and psychosis, especially where adherence is a concern.
Pharmacokinetic parameters reported in adult psychiatric patients after oral administration.
Tveito, M, et al., & Høiseth, G (2021). Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. European journal of clinical pharmacology 77(2) 215–221. DOI:10.1007/s00228-020-03002-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/33000414
Jerling, M, et al., & Sjöqvist, F (1996). The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical pharmacology and therapeutics 59(4) 423–428. DOI:10.1016/S0009-9236(96)90111-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8612387
Dumortier, G, et al., & Degrassat, K (2005). [Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives]. L'Encephale 31(4 Pt 1) 477–489. DOI:10.1016/s0013-7006(05)82409-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16389715